Conditionnement : 10mg
Synonyms:
| Description | JTE-013 is an effective and specific antagonist of S1P2. JTE-013 suppresses the specific binding of radiolabeled S1P to human and rat S1P2 (IC50s: 17 nM and 22 nM, respectively). |
| Targets & IC50 | S1P2 (rat):22 nM, S1P2 (human):17 nM |
| In vitro | JTE-013 is a S1P2 antagonist. JTE-013 (50-200 μM;?1-3 days) decreased cell viability.?JTE-013 shows 4.2% inhibition of S1P3 and does not antagonize S1P1 at concentrations up to 10 μM.?JTE-013 (10-1000 nM;?30 mins) reverses S1P-induced Akt inhibition and inhibits S1P-induced ERK activation. |
| In vivo | JTE-013 (gavage;?30 mg/kg daily for 14 consecutive days) decreases tumor size and tumor weight.?the modification of JTE-013 to produce the AB1 compound improved potency, intravenous pharmacokinetics, cellular activity, and antitumor activity in NB and may have enhanced clinical and experimental applicability. |
| Molecular Weight | 408.29 |
| Formula | C17H19Cl2N7O |
| Cas No. | 383150-41-2 |
| Smiles | CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12 |
| Relative Density. | 1.50 g/cm3 (Predicted) |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (612.31 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: < 10 mg/mL (24.49 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+90% Saline: < 10 mg/mL (24.49 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+90% (20% SBE-β-CD in Saline): < 10 mg/mL (24.49 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+90% Corn oil: 10 mg/mL (24.49 mM), Solution. 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (8.08 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
